StockData
Harrow, Inc. logo

Harrow, Inc. (HROW) company profile

HROWNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 6/30
$29.09−1.03 (-3.42%)

Close on Nov 16, 2026Market cap $1.09BP/E –Yield –

About Harrow

Pharmaceutical Preparations, SIC 2834

Harrow, Inc. is an eye-care pharmaceutical company that specializes in the development, production, and commercialization of ophthalmic treatments and compounded medications. The company operates through two primary business segments: Branded and ImprimisRx. Its portfolio includes commercial ophthalmic therapies, notably VEVYE and IHEEZO, as well as specialized formulations. Harrow serves healthcare professionals, specialized clinics, hospitals, pharmacies, and patients requiring tailored pharmaceutical solutions.

The company conducts operations across several locations in the United States, maintaining office, laboratory, and facility spaces in Carlsbad, California; Ledgewood, New Jersey; and Nashville, Tennessee. The company's principal executive offices are headquartered in Nashville, Tennessee.

Summary of the business section of Harrow's latest annual report, written by StockData.

Company profile

Company

Legal name
Harrow, Inc.
Founded
1998
Headquarters
Nashville, TN
Address
1a Burton Hills Blvd, Suite 200
Phone
(615) 733-4731
Employees
373, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
KMJ Corbin & Company LLP, Glendora, California

Stock & identifiers

Ticker
HROW
Former tickers
IMMY until Mar 12, 2019
Exchange
Nasdaq
IPO date
Sep 28, 2007
Shares outstanding
37M, Aug 6, 2026
Public float
$1.00B, Jun 30, 2025
Filer category
Large accelerated filer
Stock splits
1-for-5 reverse, Feb 8, 2013; 1-for-8 reverse, Feb 24, 2012
SEC CIK
1360214
CUSIP
415858109
ISIN
US4158581094
FIGI
BBG000QXWY44
Share class FIGI
BBG001SSTRN9
LEI
529900AP4LIRLNV8A089
EIN
45-0567010

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Mark L. BaumCHIEF EXECUTIVE OFFICER, Director3,594,256
Amir ShojaeiCHIEF SCIENTIFIC OFFICER0
Andrew R. BollPRESIDENT AND CFO814,679
Patrick William SullivanCHIEF COMMERCIAL OFFICER–
Francis William Mullery JrCEO, ImprimisRx–
Randall E. PollardCHIEF ACCOUNTING OFFICER–
John P. SaharekCEO & President, ImprimisRx467,388
Lauren P. SilvernailDirector1,000
Perry J. SternbergDirector–
Adrienne L. GravesDirector1,000

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$23.61M$33.13M$3.56M$714$120
FY2024$1.36M$21.47M$796.33K$489$91
FY2023$15.26M$3.11M$6.47M$163$92
FY2022$1.20M$9.51M$710.64K$215$89
FY2021$7.32M$8.69M$3.01M$126$99

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
Mark L. Baum
Chief Executive Officer
$754.91K$22.29M–$542.49K$14.00K$23.61M+1638%
Andrew R. Boll
President and Chief Financial Officer
$505.26K$10.17M–$258.26K$14.00K$10.95M+1189%
Francis W. Mullery
President and Chief Executive Officer, ImprimisRx Division (6)
$129.81K–$1.05M$53.26K–$1.24M–
Amir H. Shojaei
Chief Scientific Officer (7)
$441.35K–$670.57K$225.00K$5.71K$1.34M–
John P. Saharek
Former President and Chief Executive Officer, ImprimisRx Division (8)
$475.61K––$237.81K$14.00K$727.42K-2%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“of February 25, 2026, we employed 373 individuals.”

Corporate history

Events identified from SEC filings

DateEventDetails
Oct 5, 2026Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Nov 18, 2025Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Oct 10, 2025DelistingNotice of delisting from exchange (Form 25)
Oct 8, 2025DelistingNotice of delisting from exchange (Form 25)
Sep 19, 2025Auditor changeChange in certifying accountant (8-K Item 4.01)
Mar 17, 2025Late filingNotification of late filing
Jun 26, 2024Auditor changeChange in certifying accountant (8-K Item 4.01)
Sep 20, 2023Name changeName changed from HARROW HEALTH, INC. to Harrow, Inc.
Jan 23, 2023Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Dec 20, 2022ListingRegistration of securities on an exchange (Form 8-A)
Apr 20, 2021ListingRegistration of securities on an exchange (Form 8-A)
Apr 12, 2021Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Dec 17, 2018Name changeName changed from Imprimis Pharmaceuticals, Inc. to HARROW HEALTH, INC.
Jul 20, 2017Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Feb 17, 2017Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Aug 11, 2016Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Oct 20, 2015Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jan 6, 2015Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Apr 3, 2014Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Feb 7, 2013ListingRegistration of securities on an exchange (Form 8-A)
Feb 27, 2012Name changeName changed from TRANSDEL PHARMACEUTICALS INC to Imprimis Pharmaceuticals, Inc.
Jun 27, 2011BankruptcyBankruptcy or receivership (8-K Item 1.03)
Mar 31, 2011Late filingNotification of late filing
Sep 21, 2007Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Sep 21, 2007Auditor changeChange in certifying accountant (8-K Item 4.01)
Sep 12, 2007Name changeName changed from Bywater Resources, Inc to TRANSDEL PHARMACEUTICALS INC
Dec 28, 2006Auditor changeChange in certifying accountant (8-K Item 4.01)

See a number that looks wrong?